

SESSIONS

FORUMS AND WORKSHOPS (APRIL 29TH)

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

REGISTRATION & BREAKFAST

08:00 - 09:00

Morning Break

10:30 - 11:10

Medtech CEO Forum

11:10 - 12:40
CEO Forums

11:10 - Welcome and Introductions

11:15 - Crossing Borders: Navigating Medical Device Innovation Stateside

This discussion will delve into the challenges of moving from the European market, to the U.S, addressing regulatory and business hurdles encountered along the way. SurePulse Medical, a UK-based company known for its innovative approach to neonatal care, has made significant strides since inception. James Carpenter, CEO, will share experiences in device approval, FDA 510(k) clearance, whilst dealing with cyber-security requirements as well as business difficulties and opportunities whilst launching in the United States. This is an opportunity for entrepreneurs, healthcare professionals, and investors to understand the challenges and opportunities in bringing a medical innovation to a new market.

Moderated by; William Garvin, Shareholder, **Buchanan Ingersoll & Rooney PC**, **Tina Hu-Rodgers**, Shareholder & Life Sciences Industry Group Co-Leader, **Buchanan Ingersoll & Rooney PC**

Speaker: James Carpenter, CEO, **SurePulse Medical**

11:50 - Death by a 1000 cuts

Join us for a dynamic discussion on the challenges faced in product development, from navigating unclear target customer/application without thorough vetting, to managing delayed design direction changes, and balancing the pursuit of market trends with leveraging core strengths/IP. We'll delve into strategies for handling premature regulatory hurdles, navigating the balance between MVP product development and FDA requirements, and the importance of timely selection of engineering partners and contract manufacturers.

Moderated by; Bryant Grigsby, CEO, **Phoenix DeVentures**

12:25 -General Discussion (suggested topics to include but not limited to)

- Fundraising challenges and opportunities
- Overcoming barriers to market and regulatory approval
- Creating the right deals and partnerships to move your business forward
- Internationalising and company growth

12.40 - End of Forum

Participants

Tina Hu-Rodgers - Shareholder and Life Sciences Industry Group Co-Leader, **Buchanan Ingersoll-Rooney PC**

William Garvin - Shareholder, **Buchanan Ingersoll-Rooney PC**

Bryant Grigsby - CEO, **Phoenix DeVentures**

James Carpenter - CEO, **SurePulse Medical**

Pharma BD Leaders Forum

11:10 - 12:50
Pharma Leaders Forums

Chaired private and exclusive roundtable series.

11.10am (1hr 40mins) Roundtable One

- M&A, deal environment, anti-trust landscape analysis, general discussion and peer commentary from BD heads

11.10 Introductions

11.15 Current and Impending Anti-trust and Regulatory Threats

General Discussion and Peer Perspectives

- Perceptions and perspectives on current deal making environment: what are BD heads observing and how are they responding?
- How should big pharma M&A strategies evolve given the regulatory and anti-trust context?

For further information regarding the Pharma BD Leaders Forum, please contact:

Matthew Pullan, Managing Director, LSX

matt@lsxleaders.com

Lunch Break

12:50 - 14:00

Pharma BD Leaders Forum

14:00 - 15:40
Pharma Leaders Forums

2pm (2hrs) Roundtable Two – Global BD Heads *only*

Pier discussion and exploration of solutions to presented challenges.

Potential topics to include:

- IRA developments
- M&A landscape
- Current challenges and success stories
- Anti-trust
- Regulatory update
- AI and relevance, impact on deal making

For further information regarding the Pharma BD Leaders Forum, please contact:

Matthew Pullan, Managing Director, LSX

matt@lsxleaders.com

SESSIONS

FORUMS AND WORKSHOPS (APRIL 29TH)

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

Medtech BD Leaders Forum

14:00 - 15:40

Medtech Leaders Forums

Join our exclusive, invite only, Medtech BD Leaders Forum—an unparalleled gathering of 15-20 industry trailblazers, including top-tier BD leaders and private equity executives.

Our forum will include insightful conversations, featuring case studies which foster candid and open dialogue about the challenges shaping the Medtech landscape.

Connect with like-minded professionals, forge strategic alliances, and expand your professional network. The forum provides a unique environment for fostering meaningful connections and gain valuable insights that will empower your strategic decision-making.

Our forum operates under ? **Chatham House Rule:** Promoting a free-flowing exchange of ideas, the Chatham House Rule ensures a confidential and productive environment, encouraging open and honest discussions.

Biotech Startup CEO Forum

16:20 - 17:40

CEO Forums

16:00 - Welcome and Introductions

Moderator: Fiona McFarlane, Legal Director, Bird & Bird

16:05 - *Early Considerations for Life Sciences Companies – Funding and beyond*

This will be a session for executives of early-stage life sciences and healthcare companies to share their experiences of running a start-up. There will be a short introduction to venture capital financing and other foundational issues, followed by a panel discussion and Q&A session where the attendees can ask questions of company representatives who have successfully navigated the early stage funding arena and investor-side representatives who provide funding to early-stage companies. The session will be operated under the Chatham House Rule to promote a free-flowing exchange of ideas in a confidential and productive environment and to encourage open and honest discussions.

Fiona McFarlane, Legal Director, Bird & Bird
Mario Subramaniam, Partner, Bird & Bird

16:35 - Case Study

Jette Cowan, Head of Commercial, Pharmaceutical, RSSL

17:05 - CEO-Led Case Study - Successful Adaptation of Fundraising Strategy in the Life Sciences/Biotech Sector

- Initially funded to Phase 1 for lead asset, planned Series A for Phase 2 study
- Market shift led to investor demand for more de-risking data before committing to larger funding
- Adapted strategy by advancing FDA "IND" opening, a significant value inflection point
- Successfully opened pre-Series A convertible note for smaller Phase 2a study, paving the way for larger funding round with a leading VC partner

John Boghossian, CEO, Kanna Health

17:25 - General Discussion and Q&A

17.40 - End of Forum

Pharma Digital Leaders Forum

16:20 - 17:40

Pharma Leaders Forums

The forum will be bringing together pharma execs who are leading digital strategy, digital transformation & digital innovation within their companies, for benchmarking, peer advice and networking.

16:20 - Welcome and Introductions

Richard Cassidy, SVP Rx+ Business Accelerator, Astellas Pharma

16:25 - Learnings from a Phase V Study: Digital RWE Generation for Migraines

Beth Wolff, Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck

16:45 – Building Sustainable, Value-Based Strategic Digital Health Partnerships

Gregoire Guillet, Chief Business and Value Officer, WeHealth Digital Medicine, Servier

17:05 - AI Enabled Prediction of Clinical Trial Success

Christian Hein, Former VP, Global Head of Digital Transformation & Innovation Execution, Novartis

17:25 – Group Discussion

Themes/ topics the group will be looking to discuss;

- How are companies continuing to build their digital strategy and capabilities?
- What are the persisting challenges in scaling digital and analytics?
- Recruiting & retaining talent in the digital space
- Effective partnerships – what has been successful?
- AI use in Pharma (analytics, leveraging RWE, AI modelling & increasing efficiency & effectiveness) – How well is this working?

17.40 - End of Forum

Participants

Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck

Christian Hein - Executive Advisor, Health Tech, Independent

Gregoire Guillet - Chief Business and Value Officer, WeHealth Digital Medicine, Servier

Moderator: Richard Cassidy - SVP Rx+ Business Accelerator, Astellas Pharma

SCHEDULE

FORUMS AND WORKSHOPS (APRIL 29TH) -

LSX HealthTech Leaders
29th-30th April 2024
Business Design Centre
London

TIME	CEO FORUMS	PHARMA LEADERS FORUMS	MEDTECH LEADERS FORUMS
08:00	08:00 - REGISTRATION & BREAKFAST	08:00 - REGISTRATION & BREAKFAST	08:00 - REGISTRATION & BREAKFAST
10:00	10:30 - Morning Break	10:30 - Morning Break	10:30 - Morning Break
11:00	11:10 - Medtech CEO Forum	11:10 - Pharma BD Leaders Forum	
12:00	12:50 - Lunch Break	12:50 - Lunch Break	12:50 - Lunch Break
14:00		14:00 - Pharma BD Leaders Forum	14:00 - Medtech BD Leaders Forum
16:00	16:20 - Biotech Startup CEO Forum	16:20 - Pharma Digital Leaders Forum	

SESSIONS

FORUMS AND WORKSHOPS (APRIL 30TH)

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

REGISTRATION & BREAKFAST

08:00 - 09:00

MORNING BREAK

10:30 - 11:10

Healthtech CEO Forum

11:10 - 12:10
CEO Forums

Pathways to success: Navigating Growth in Healthtech

This session is for established healthtech senior executives to share their experiences of growing and scaling up businesses in the healthtech sector.

11.10 – Introductions

Moderators: Susanna Stanfield, Head of Life Sciences Practice, Withers Tech & Thomas Meyers, Partner, Withers US

11.20 – Panel Discussion

There will be a panel discussion of senior executives from healthtech companies who will share their experiences of growing and scaling up their businesses in the healthtech sector. Topics to cover include:

- Fundraising and attracting investors
- Navigating turbulent market conditions
- Product development cycle
- The role of collaborations and business combinations
- Expanding to US and other jurisdictions

Bea Bakshi, CEO & Co-Founder, C the Signs

Inga Deaking, Principal, Molten Ventures

Anna Dixon, Chief Operating Officer, Binx Health

11.50 – Q&A and Closing Remarks

Attendees will be given the opportunity to ask the panellists questions arising from the panel discussion and share their own experiences.

Participants

Thomas Meyers - Partner, Withers US

Susanna Stanfield - Head of Life Sciences Practice, Withers Tech

Bea Bakshi - CEO & Founder, C the Signs

Inga Deakin - Principal, Molten Ventures

Anna Dixon - Chief Operating Officer, Binx Health

IPO Workshop

11:10 - 12:15
General Workshops

11.10 - Welcome and Introductions

Moderator: Zafar Aziz, Director, Head of Strategic Sales & DR Investor Relations Advisory Group, Deutsche Bank

11.15 – Opening Presentation – IPOs: what is the current state of the market and what should companies expect from their advisors?

Presenter: James Taylor, Co-Head of Investment Banking, Deutsche Numis

11.45 – Expert Panel Discussion – IPO opportunities: US vs UK?

- How is London is changing its rules to make it easier for companies to list?
- Is there a valuation difference between the UK and the US?
- Are you a small fish in a big pond if you choose the US?
- Is it better to be dual-listed?
- With the rise of passive funds, is indexation an important consideration?
- How should you approach investor relations if dual listed?
- Execution of listing: Necessary steps to prepare
- Life as a public company

Moderator: Zafar Aziz, Director, Head of Strategic Sales & DR Investor Relations Advisory Group, Deutsche Bank

James Taylor, Co-Head of Investment Banking, Deutsche Numis

Tim Davis, Regional Head, UK Primary Markets, London Stock Exchange

Isabella Schidrich, Senior Managing Director, NASDAQ

12.15 – Q&A and Discussion

LUNCH BREAK

12:50 - 14:00

Biotech Growth CEO Forum

14:00 - 15:40
CEO Forums

14:00 - Welcome and Introductions

Moderator: Elizabeth Rhodes, Partner, Goodwin

14:05 - Raising capital to support later-stage growth

- Market Update – Later stage rounds are challenging to get away and IPO market increasingly pressurising the valuations of private companies.
- Valuation Pressure – dangers of structuring preference rights to prop up a higher valuation / avoid a down round.
- How to continue to incentivisation when there is an increasing liquidation preference.
- How to set yourself up for a successful exit

Elizabeth Rhodes, Partner, Goodwin
Kenny Walker-Durrant, Partner, Goodwin

14:40 - CEO-Led Case Study

15:00 - CEO-Led Case Study

15:20 - General Discussion and Q&A

15:40 - End of Forum

M&A Workshop

14:00 - 15:00
General Workshops

The M&A workshop led by Hogan Lovells will consider the different means through which early/late stage biotech and pharma assets can be most effectively monetised, including through M&A, collaboration/JV and licensing structures.

The workshop will consider the pros and cons of each structure from both a seller's and buyer's/investor's perspective. The format will be interactive and factor in current trends (e.g. the increased use of AI and integration of healthcare services into technology platforms) and growth products and therapies (e.g. ADC's, RLT's, GLP-1, health span and pre-emptive medicine and chronic/orphan disease).

SCHEDULE

FORUMS AND WORKSHOPS (APRIL 30TH) -

LSX HealthTech Leaders
29th-30th April 2024
Business Design Centre
London

TIME	CEO FORUMS	GENERAL WORKSHOPS
08:00	08:00 - REGISTRATION & BREAKFAST	08:00 - REGISTRATION & BREAKFAST
10:00	10:30 - MORNING BREAK	10:30 - MORNING BREAK
11:00	11:10 - Healthtech CEO Forum	11:10 - IPO Workshop
12:00	12:50 - LUNCH BREAK	12:50 - LUNCH BREAK
14:00	14:00 - Biotech Growth CEO Forum	14:00 - M&A Workshop

REGISTRATION & BREAKFAST

08:00 - 09:00

LSX Welcome Address

09:00 - 09:10

Participants

Nadia Konneh - Senior Conference Director, Healthtech Lead, LSX

Future of Digital Health: How Can We Accelerate?

09:10 - 09:50

Identifying innovative frontiers in digital health and forging new technological paths are vital for improving healthcare accessibility and delivery. A panel of industry leaders discuss strategies for navigating the evolving landscape effectively.

- Examining Industry evolution - a look at successes and failures
- Identifying future digital health frontiers for innovation
- Forging new technological paths for enhanced healthcare delivery

Participants

Søren Østergaard - VP, Strategic Development & Digital Transformation, Global Drug Discovery, Novo Nordisk

Emre Ozcan - VP, Global Head of Digital Health, Merck

Sridevi Nagarajan - Head Digital Regulatory Strategy, AstraZeneca

Farnaz Behrooz - Head of Pharma, Huma

Nicolas Pivert - Senior Business Director, Cardiac Rhythm Management, Western Europe, Medtronic

Moderator: Fraser Wood - Digital Strategist (Former Global Incubator Lead, MSD), Independent

Balancing Patient-Centric Digital Therapeutics with Scalable Profitability

09:50 - 10:30

The healthcare landscape is evolving with a strong emphasis on patient-centred care and the integration of DTx, this discussion reflects this shift and addresses the challenges and opportunities it presents. This includes the need to strike a balance between patient-focused solutions and sustainable business models, navigate evolving regulatory considerations, and foster collaborations between DTx companies and pharmaceutical firms to enhance patient care. In this dynamic context, the panel aims to provide insights and strategies for effectively navigating the evolving healthcare terrain.

- Insights from 2023 - Lessons from DTx companies that didn't succeed
- Unlocking DTx potential and commercialization - Are we there yet
- Agile approaches to business and go-to-market models are crucial
- Evaluating the effectiveness of DTx partnerships with Pharma

Participants

Marc Sluijs - Managing Partner, DigitalHealth.Network

Kamran Adle - VC Investor, Octopus Ventures

Christian Lautner - Managing Partner, Heal Capital

Hannes Klöpper - CEO, HelloBetter

Marek Ostrowski - Founder & CEO, Prosoma

Moderator: Laura Wamprecht - Former Managing Director, Flying Health

MORNING BREAK

10:30 - 11:10

Going Beyond the Hype - Exploring New Applications of AI/ML

11:10 - 12:00

The healthtech landscape is rapidly evolving with data technology, advanced analytics, and AI reshaping healthcare across sectors. Healthtech companies should be keenly interested in leveraging these innovations for precise diagnostics, personalized treatments, and ground-breaking discoveries while enhancing competitiveness through strategic AI partnerships, ultimately driving improved patient outcomes and shaping the future of healthcare

- Harnessing data tech and AI for disease understanding and patient outcomes
- AI's pioneering role in healthcare, medtech, pharma innovation and partnerships
- Maximizing AI's potential in pharma research, remote care, and medtech

Participants

Valerie Hepp - Digital and PHC Partnering Europe and Asia Lead, Roche

Szabolcs Nagy - Co-Founder, CEO, and Founder Director, Turbine

Yannis Pandis - Sr Director, AI, ML Analytics and Data Functional Lead, Pfizer

Ian Mulvany - CTO, BMJ

Adam Laing - Co-Founder & CEO, IMU Biosciences

Moderator: Colin Weller - General Manager, Evidence Generation Platform, Medable

Digital Health & DTx Partnerships – A Recipe For Success

12:00 - 12:50

- Navigating diverse partnership models - identifying effective approaches
- Are Pharma companies the preferred partners for digital health start-ups
- Investor and Pharma expectations from digital health Companies - bridging the gap
- Exploring the Dynamics of Digital Health and DTx collaborations - challenges and opportunities

Participants

Marko Kuisma - Partner, Innovestor

Gregoire Guillet - Chief Business and Value Officer, WeHealth Digital Medicine, Servier

Shahram Sharif - CEO, Liva Healthcare

Ashutosh Malhotra - Director, Digital Health Strategy & Partnerships, Europe, Daiichi Sankyo

Moderator: Tina Tan - Executive Editor, FirstWord HealthTech

SESSIONS

DAY 1 – MONDAY 29 APRIL - 29/04/2024

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

LUNCH BREAK

12:50 - 14:00

Navigating Pharma's Path To Launching Digital Health Products: Overcoming Challenges And Driving Innovation

14:00 - 14:50

2024 heralds a turning point with the integration of digital engagement and AI into pharmaceutical workflows, promising to revolutionize drug marketing, development, and patient care. These dynamics underscore the industry's commitment to delivering more efficient and patient-centric healthcare solutions. By gaining a deep understanding of these aspects, digital health companies can make informed decisions, refine their business strategies, and position themselves effectively within the pharmaceutical industry's evolving landscape.

- Addressing the Pharma Industry's Biggest Challenges
- Making Pharma-Pharma Collaboration a Reality
- Effective Go-to-Market Strategies in Evolving Healthcare Models
- Is 2024 the Dawn of Digital Engagement and Launches
- Integrating AI into Pharma Workflows

Participants

Martin Alexander Gershon - Managing Partner & CIO, Endeavor Venture Fund

Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck

Christian Hein - Executive Advisor, Health Tech, Independent

Dominic James - Global Head of Digital Health Innovation & Alliances, MSD

Moderator: Samantha Peacock - Senior Associate, Latham & Watkins

Panel: Embracing Digital Technologies & Scaling Patient-Centric Clinical Trials

14:50 - 15:40

- How are new digital innovations revolutionising clinical trials?
- Beyond AI/ML - Overview of emerging clinical trial technologies
- Ensuring diversity, equity, and inclusion in digitised clinical trials

Participants

Mats Berggren - Head of Search and Evaluation, Digital Innovation, External R&D, Merck Healthcare

Aedan Martin - Global Information & Technology Business Partner, Roche

Marc Jones - CEO, Altoida

Moderator: Andrew Mackinnon - Executive General Manager, Customer Value, Medable

AFTERNOON BREAK

15:40 - 16:20

Healthtech At Scale In Europe – Rising Above The Fragmented Digital Markets

16:20 - 17:00

In Europe, fragmented healthcare systems, strict data privacy laws (GDPR), regulatory complexities, interoperability challenges, language diversity, and varied reimbursement models pose obstacles for healthtech firms. Nevertheless, opportunities lie in Europe's vast market, healthtech hubs, telehealth demand, research collaborations, digitization of health records, partnerships, government backing, and rising health awareness. Success hinges on companies effectively addressing these challenges and seizing these opportunities in the European healthtech sector.

- Is Europe optimal for healthtech scale-up
- Navigating regulatory hurdles for digital health product approval and reimbursement in Europe
- Strategies for thriving in Europe's fragmented digital health markets

Participants

Moderated by: Chris Hamilton - Partner, Global Head of Life Sciences, Odgers Berndtson

Lucy Jones - Chief Clinical Officer, Oviva

Ranjan Singh - Co-founder & CEO, HealthHero

Joao Barbosa da Silva - Senior Associate, re.Mind Capital

Klaudia Eriksson Philipp - Director, Global Digital Innovation & Alliances, Europe & US, Pfizer

Matthew Bardsley - Head of International, Telstra Health

Reality Check: DTX Investment Landscape, Still Hot or Cooling Down?

17:00 - 17:40

In a shifting financial landscape marked by intensified competition for investment, DTx startups are facing challenges reminiscent of the 2008/2009 economic crisis, including dwindling individual investment amounts and layoffs in the digital health sector. As the industry undergoes a market shakeout, this session explores how DTx startups can effectively prepare for investment rounds in this highly competitive environment.

- How do investors assess the current investment landscape for DTx startups, and what key factors influence investment decisions in this competitive environment
- What specific strategies and criteria do investors look for in DTx startups to determine their readiness for investment rounds
- With a sea of startups vying for attention, how can a company distinguish its pitch

Participants

Shamikh Parekh - Investor, Octopus Ventures

Ingrid Teigland Akay - Managing Partner, Hadean Ventures

Erki Mölder - Managing Partner, Verge Healthtech Fund

Josep Ll Sanfeliu - Managing Partner, Asabys Partners

Dominick Kennerson - SVP, HealthTech, HSBC Innovation Banking

Moderator: Andy Molnar - CEO, Digital Therapeutics Alliance

SESSIONS

DAY 1 – MONDAY 29 APRIL - 29/04/2024

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

CLOSE OF DAY 1 AGENDA – NETWORKING PARTY

17:40 - 19:45

Join us at the end of day one in the exhibition hall for an unforgettable night filled with entertainment and thrilling surprises.

Evening Highlights:

- **17:40 - 19:30:** Savour a selection of fine drinks and exquisite culinary offerings, including cocktails, canapés, sushi, and Iberico ham carving
- **Entertainment:** Enjoy live music from our band and breath-taking performances by an aerialist
- **Games & Prizes:** Engage in fun games with a chance to win fabulous prizes throughout the evening
- **18:15 - 19:40:** Be mesmerized by the magic and illusions performed by our skilled magician
- **19:30:** Raise a glass of Prosecco and enjoy some anniversary cakes whilst we announce our prize winners
- **19:45:** Official closing of the reception

Enjoy:

- **Cocktails:** Delight in exclusive cocktails served at the HSBC and Qualio bars. Choose from Daiquiri, Espresso Martini, Pimm's & Lemonade, or Cosmopolitan
- **Photo Opportunities:** Capture memorable moments at our photo booth
- **Sweet Treats:** Don't miss our pick-a-mix stand for a sweet finale to your evening

SCHEDULE

DAY 1 – MONDAY 29 APRIL - 29/04/2024

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

TIME	
08:00	08:00 - REGISTRATION & BREAKFAST
09:00	09:00 - LSX Welcome Address 09:10 - Future of Digital Health: How Can We Accelerate? 09:50 - Balancing Patient-Centric Digital Therapeutics with Scalable Profitability
10:00	10:30 - MORNING BREAK
11:00	11:10 - Going Beyond the Hype - Exploring New Applications of AI/ML
12:00	12:00 - Digital Health & DTx Partnerships – A Recipe For Success 12:50 - LUNCH BREAK
14:00	14:00 - Navigating Pharma's Path To Launching Digital Health Products: Overcoming Challenges And Driving Innovation 14:50 - Panel: Embracing Digital Technologies & Scaling Patient-Centric Clinical Trials
15:00	15:40 - AFTERNOON BREAK
16:00	16:20 - Healthtech At Scale In Europe – Rising Above The Fragmented Digital Markets
17:00	17:00 - Reality Check: DTX Investment Landscape, Still Hot or Cooling Down? 17:40 - CLOSE OF DAY 1 AGENDA – NETWORKING PARTY

REGISTRATION & BREAKFAST

08:00 - 09:00

LSX Welcome Address

09:00 - 09:10

Participants

Nadia Konneh - Senior Conference Director, Healthtech Lead, LSX

Bridging the Digital Divide - Healthcare's Journey to Technological Advancement

09:10 - 09:50

The global digital healthcare market is expected to hit \$504.4 billion by 2025. Yet, the healthcare industry is lagging behind other industries in digital transformation, with only 7% of companies having a digital strategy. To thrive in this tech-driven era, healthcare leaders need to develop and implement a digital strategy that leverages technology to improve patient care and operations.

- How and why to build a digital strategy for your company
- A review of current 'digital health trends', how can they be leveraged by biotech/medtech SME's to improve their product offering
- How digital transformation can assist companies to scale

Participants

Moderator: Jean-Francois Rivassou - Partner, Kurma Partners

Thomas Hummel - Head of Digital Transformation, Fresenius Kabi

Aneta Gawlowska - Global Business Development & Strategy Director, Medtronic

Alexander Stanke - COO & Managing Director, Preventicus

Access All Areas – How Healthtech Is Tackling The Equity Challenge

09:50 - 10:30

- How companies can truly represent the populations they serve
- The forgotten equity elements in product design and clinical trials
- Building trust in digital technology, AI and Data Use

Participants

Andrew Davies - Digital Health Lead, ABHI

Priya Oberoi - Founding General Partner, Goddess Gaia Ventures

Andrew Miles - Head of Healthcare and Life Sciences, EMEA, Google Cloud, Google

Moderated By: Mark Davies - Chief Health Officer, IBM

Geoffrey D'Hondt - Investment Manager, Heran Partners

Anushka Patchava - Co-Founder, Wellx

MORNING BREAK

10:30 - 11:10

Real-World Evidence and Real-World Data: The Prescription for Commercial Success

11:10 - 12:00

The FDA and EMA have increasingly embraced real-world evidence (RWE) and real-world data (RWD) in regulatory decisions, with around 75% of new drug applications in 2020 including RWE at the FDA. However, differences exist between the agencies, and RWE strategies approved by one may not be accepted by the other, necessitating early dialogues. Challenges include improving data quality and privacy, while the future of RWE lies in AI and ML for rapid data analysis and the need for rigorous validation and trust in emerging RWE solutions.

- Identifying and Accelerate the development of new drugs, therapies and devices
- The role of RWE and RWD to support clinical trials and improve patient outcomes
- Can RWE/RWD optimize commercialization and pricing strategies
- Accessing high-quality RWD, ensuring data reliability, relevance, and security, while optimizing data collection

Participants

Anders Borglykke - Vice President, Real-World Science, Data Science, Novo Nordisk

Ventsislav Dobrev - Global Lead Digital Health, Ypsomed

Moderator: Nicole Mather - Partner, Life Sciences & Health Data Lead, IBM

Marc Jones - CEO, Altoida

Remote Patient Monitoring: Redefining the Standard-of-Care & Clinical Research

12:00 - 12:50

The adoption of remote patient monitoring and telehealth solutions continues to accelerate as health systems struggle with shortages of healthcare professionals and beds. With numerous benefits, ranging from reductions in hospital acquired infections to massively increased patient satisfaction, virtual hospitals are here to stay. This panel explores the opportunities to leverage virtual hospitals to improve the current standard-of-care and develop the medicines that will underpin the future standard-of-care.

- How to improve patient experience to increase treatment adherence and patient outcomes with virtual wards
- Reducing the time-toxicity of new therapies
- Virtual hospitals for generating real world data

Participants

Yacine Hadjiat - Digital Health Innovation, MBRU

Toby Basey-Fisher - CEO, Entia

Baudouin Hue - Partner, Karista

Sam Ewing - Global Head of Pharma Partnerships, Doccla

Andrea Zitna - Partner, Speedinvest

LUNCH BREAK

12:50 - 14:00

How Is Healthtech Building A Patient-Focused NHS?

14:00 - 14:40

Embracing HealthTech innovation is pivotal in addressing the enduring challenges confronting the NHS. However, many stakeholders in the sector encounter obstacles in adopting and realizing the full potential of these solutions. How can we facilitate greater adoption and elevate the healthcare experience for both patients and clinicians?

- Overcoming healthtech adoption challenges
- Leveraging healthtech for long-term healthcare challenges
- Harmonizing patient and physician perspectives

Participants

Michael Macdonnell - Global Head of Healthcare & Pharma Partnerships, Huma

Mark Davies - Chief Health Officer, IBM

Peter Hames - CEO, BigHealth

Anna Dijkstra - Innovation Director, Healthcare & Life Sciences, EMEA, Microsoft

Moderator: Barnaby Pickering - Senior Writer - Medtech Insight, RHA Communications

From Code to Care – Digital's Role in Crafting Next-Gen Medical Devices

14:40 - 15:20

Despite prevailing investment downturns, the upward trajectory of digital and AI breakthroughs continues to elevate the precision, efficiency, and personalization of medical devices. This discussion will deeply explore digital integrations and AI's expansive capabilities in healthcare, while also dissecting crucial integration challenges such as innovation, regulatory compliance, and privacy considerations

- The latest digital applications across sub-sectors in medical device companies
- Unpacking strategies for effective utilization of AI-generated data in medical enterprises
- Navigating the essentials: data, privacy, regulations, and reimbursement insights for CEO's

Participants

Robert Lauritzen - CEO, Cerebriu

Moderator: Jonas Hjortshøj - Founder & Principal, Pivot Healthtech Partners

Rudolf Vohren - CEO, Nano4Imaging

Manios Dimitrakakis - CEO, Panda Surgical

Ben Finlay - Co-Founder, Ranvier.ai

Investing In Cutting Edge Tech - What's The Next Big Thing On The Horizon?

15:20 - 16:00

Amidst numerous emerging trends hailed as the future of healthtech, the endurance and lasting impact of these innovations on the healthcare industry are yet to be determined. Rapid advancements in remote monitoring technology, big data analytics, and AI have created uncharted territory for innovators, accompanied by a host of new challenges demanding careful consideration. In this panel, seasoned industry experts delve into the current forefront trends in healthtech and assess their potential longevity and significance.

- Investment opportunities in emerging tech, what's hot
- The visionaries' perspective, insights from industry leaders on what's next in their pipelines
- Navigating uncertainty, strategies for making informed tech investments and acquisitions

Participants

Moderator: Tony Cheng-Fu Chang - Sr. Business Developer, BII

Edward Kliphuis - Partner, Sofinnova Partners

Yara Alenazi - Investor, HealthTech, MassMutual Ventures

Inga Deakin - Principal, Molten Ventures

Christian Lautner - Managing Partner, Heal Capital

CLOSE OF CONGRESS

16:00 - 16:05

SCHEDULE

DAY 2 – TUESDAY 30 APRIL - 30/04/2024

LSX HealthTech Leaders

29th-30th April 2024
Business Design Centre
London

TIME	
08:00	08:00 - REGISTRATION & BREAKFAST
09:00	09:00 - LSX Welcome Address 09:10 - Bridging the Digital Divide - Healthcare's Journey to Technological Advancement 09:50 - Access All Areas – How Healthtech Is Tackling The Equity Challenge
10:00	10:30 - MORNING BREAK
11:00	11:10 - Real-World Evidence and Real-World Data: The Prescription for Commercial Success
12:00	12:00 - Remote Patient Monitoring: Redefining the Standard-of-Care & Clinical Research 12:50 - LUNCH BREAK
14:00	14:00 - How Is Healthtech Building A Patient-Focused NHS? 14:40 - From Code to Care – Digital's Role in Crafting Next-Gen Medical Devices
15:00	15:20 - Investing In Cutting Edge Tech - What's The Next Big Thing On The Horizon?
16:00	16:00 - CLOSE OF CONGRESS